Daiichi Sankyo Company, Limited (TYO:4568)
Japan · Delayed Price · Currency is JPY 3,518.00
-47.00 (-1.32%)
Sep 2, 2025, 3:30 PM JST
Daiichi Sankyo Company Revenue
Daiichi Sankyo Company had revenue of 474.60B JPY in the quarter ending June 30, 2025, with 8.81% growth. This brings the company's revenue in the last twelve months to 1.92T, up 14.09% year-over-year. In the fiscal year ending March 31, 2025, Daiichi Sankyo Company had annual revenue of 1.89T with 17.77% growth.
Revenue (ttm)
1,924.68B
Revenue Growth
+14.09%
P/S Ratio
3.38
Revenue / Employee
97.38M
Employees
19,765
Market Cap
6,511.61B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1,886.26B | 284.57B | 17.77% |
| Mar 31, 2024 | 1,601.69B | 323.21B | 25.28% |
| Mar 31, 2023 | 1,278.48B | 233.59B | 22.36% |
| Mar 31, 2022 | 1,044.89B | 82.38B | 8.56% |
| Mar 31, 2021 | 962.52B | -19.28B | -1.96% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,196.21B |
| Takeda Pharmaceutical Company | 4,480.25B |
| HOYA Corporation | 876.09B |
| Otsuka Holdings | 2,401.70B |
| Terumo | 1,037.94B |
| Astellas Pharma | 1,944.99B |
| Shionogi & | 440.50B |
| Olympus | 969.02B |
Daiichi Sankyo Company News
- 2 days ago - Daiichi Sankyo Announces the Development of a Fixed-Triple Combination Lipid-Lowering Tablet to Address Persistent Gaps in the Management of Elevated LDL-C - Business Wire
- 2 days ago - Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C - Business Wire
- 19 days ago - Daiichi Sankyo Presents New Data in Small Cell Lung Cancer and Updates Across ADC Portfolio Highlighting Progress in Creating New Standards of Care for Patients with Lung Cancer at WCLC - Business Wire
- 4 weeks ago - Daiichi Sankyo Company, Limited (DSKYF) Q1 FY2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Daiichi Sankyo has inventory buffer, will expand production capacity in Ohio to mitigate US tariffs - CFO - CNBC
- 4 weeks ago - Daiichi Sankyo reports Q1 results - Seeking Alpha
- 6 weeks ago - AstraZeneca, Daiichi Sankyo get U.S. breakthrough therapy status for Enhertu - Seeking Alpha
- 6 weeks ago - ENHERTU® Plus Pertuzumab Granted Breakthrough Therapy Designation in the U.S. as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer - Benzinga